12:35 PM EST - Bausch Health Companies Inc. : Today announced it has initiated a clinical trial program in Canada evaluating an investigational use of VIRAZOLE® (Ribavirin for Inhalation Solution, USP) in combination with standard of care therapy to treat hospitalized adult patients with respiratory distress due to COVID-19. Because ribavirin is a synthetic nucleoside that works to stop viral replication, VIRAZOLE may be effective in reducing the severity of COVID-19 infection. Bausch Health Companies Inc.
shares T.BHC are trading up $0.17 at $25.42.
